BioSpace News Archive

RxSight, Inc., an ophthalmic medical device company, announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.

Immuneering Corporation announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering.

Baxter International Inc., a leading global medical products company, reported results for the second quarter of 2021.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 851,306 shares at $17.62 per share.

Cytocom, Inc., a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET).

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced that it will report its financial results for the second quarter, ended June 30, 2021.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, announced the appointments of Pamela Cramer as Chief Human Resources Officer and Linda Shapiro Manning, M.D., Ph.D., as Senior Vice President, Clinical.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021

Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea, announced that the Company has opened TheVivos Institute training center in Denver, Colorado.